hepatocellular carcinoma
Conditions
Interventions
Sponsors
Beijing Youan Hospital Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 2007.1-2015.6 hospitalization and adequate preoperative auxiliary examination (laboratory examination, enhanced CT/MRI examination); 2. pathological diagnosis was HCC; 3. BCLC stage A or B1; 4. receive TACE sequential ablation therapy (or without TACE) and the evaluation was complete ablation according to the mRECIST criteria; 5. each patient was followed up until recurrence or the end of 2018.6; 6. Regular follow-up: more than 3 years or until death after ablation. The content of follow-up: reexamine monthly in the first three months, included abdominal enhanced CT/MRI, liver function, AFP, blood routine and coagulation function. If no recurrence occurs, the examination above are repeated with an interval of three months.
Exclusion criteria
Exclusion criteria: 1. The follow-up was less than three years; 2. without the preoperative pathological diagnosis; 3. BCLC stage >B1; 4. the evaluation was incomplete ablation according to the mRECIST criteria; 5. history of intervention therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence;recurrence free survival;SEN, SPE, ACC; | — |
Countries
China
Contacts
Public ContactChunwang Yuan
Beijing Youan Hospital Capital Medical University
Outcome results
None listed